Fulcrum Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses), averaging +6.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.21 | $-0.21 | +0.0% | Beat | |
| Q1 FY26 | $-0.31 | $-0.25 | +19.4% | Beat | |
| Q4 FY25 | $-0.31 | $-0.31 | +0.0% | Beat |
Back to FULC overview · FULC holders · FULC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.